Dr. Kyle Loh
Professor and the Anthony DiGenova Endowed Faculty Scholar, Stanford University
Type 1 Diabetes in an autoimmune disease. Therefore, the ability to efficiently generate human immune cell-types in vitro, and to engineer them with desired combinations of mutations, could be used to eventually understand and treat Type 1 Diabetes. To this end, the Loh group seeks to reconstitute the development of human blood-forming hematopoietic stem cells (HSCs) and T cells in vitro from human pluripotent stem cells (hPSCs). Advances by the Loh Laboratory have led to strategies for efficiently generating primitive streak, endoderm and foregut precursors from hPSCs. He has collaborated with Drs. Kim and Shizuru in prior studies of HSC and pancreas cell differentiation. His laboratory is jointly affiliated with the Stanford Diabetes Research Center, the Institute for Stem Cell Biology & Regenerative Medicine, and the Department of Developmental Biology.